Who benefits most from dual and triple incretin drugs?

Who benefits most from dual and triple incretin drugs?

The people who stand to gain the most are those with type 2 diabetes and obesity who have not achieved adequate weight loss or blood sugar control with existing GLP-1 receptor agonists alone. Dual and triple agonists target multiple hormone receptors simultaneously—GLP-1, GIP, and glucagon—which produces synergistic effects on weight and glucose. For example, tirzepatide (a GIP/GLP-1 dual agonist) reduced HbA1c and body weight more effectively than selective GLP-1 agonists like semaglutide in clinical trials [5]. Retatrutide, a triple agonist, showed significant reductions in HbA1c and dose-dependent weight loss in people with type 2 diabetes, with higher doses producing greater effects [8]. This means patients who need more aggressive metabolic intervention are the primary beneficiaries.

Additionally, people with metabolic dysfunction-associated steatohepatitis (MASH) and coexisting obesity or type 2 diabetes may benefit. Multiple reviews highlight that dual and triple incretin agonists are becoming an attractive treatment option for MASH, with phase 2 trials showing histological improvements in liver fat and inflammation [1][3]. The extra benefit comes from glucagon receptor activation, which increases energy expenditure—something single GLP-1 agonists do not do [6]. In preclinical models, optimized triple agonists normalized body weight in obese mice and enhanced energy expenditure beyond what dual agonists achieved [6].

What are the trade-offs and risks?

The central trade-off is that greater efficacy comes with a higher burden of side effects and unresolved safety questions. Gastrointestinal side effects (nausea, vomiting, diarrhea) are common with dual and triple agonists, and retatrutide caused a dose-dependent increase in heart rate and mild cardiac arrhythmias in trials, raising cardiovascular safety concerns that require long-term outcome studies [8]. This means patients with pre-existing heart conditions may need careful monitoring.

Another major risk is during pregnancy. A 2025 animal study found that tirzepatide exposure during pregnancy in mice caused progressive maternal weight loss, pale and mottled livers (indicating metabolic disturbance), and significantly smaller embryos with growth restriction, suggesting compromised nutrient transfer across the placenta [7]. This highlights potential reproductive risks, and the authors call for further research to determine if similar outcomes occur in humans. For now, these drugs are not recommended during pregnancy.

Cost and accessibility are also barriers. Dual and triple agonists are newer and likely more expensive than single GLP-1 agonists, and the potential improvement in efficacy must be weighed against cumulative side-effect burden, drug-drug interactions, and costs [3]. The optimal ratio of glucagon to GIP to GLP-1 agonism is still uncertain, and whether GIP agonism or antagonism is better remains debated [3].

Where does the evidence agree and where does it conflict?

The studies strongly agree that dual and triple agonists outperform single GLP-1 agonists on weight loss and glycemic control. Tirzepatide's superiority over semaglutide is documented in multiple reviews [2][4][5], and retatrutide's dose-dependent weight loss is confirmed in phase 2 trials [8]. Preclinical data also consistently show that triple agonists enhance energy expenditure beyond dual agonists [6]. This convergence across human and animal studies strengthens the conclusion that multi-receptor targeting is more effective.

However, there is conflict about the role of GIP agonism. Early short-term experiments in people with type 2 diabetes showed that GIP had little ability to stimulate insulin secretion, leading to a pessimistic view of GIP as a therapeutic target. Yet tirzepatide, which activates GIP receptors, produces better outcomes than GLP-1 alone, and researchers are actively investigating why long-term GIP agonism may work differently than short-term exposure [5]. This means the mechanism is not fully understood, and some uncertainty remains about whether GIP agonism or antagonism is the optimal strategy [3].

Another area of disagreement is whether GLP-1 agonists have direct effects on the liver or work indirectly through weight loss and improved insulin resistance. Some reviews argue that the dominant mode of action is upstream on weight, and that direct anti-fibrotic effects are not proven [3]. Others note that phase 2 trials show histological improvements in MASH, but whether this is independent of weight loss is unclear [1]. This matters for patients with liver disease who may not be obese.

About These Sources

This answer is built on 8 peer-reviewed studies — published from 2022 to 2026, 4 from 2024 or later, 5 in Q1 journals, collectively cited 585 times — selected as the most relevant from 9 studies that passed quality screening, drawn from 39 papers retrieved from a database of over 500 million.

Sources used in this answer

Related research questions